Richard S Matulewicz1, Alfred Rademaker2, Joshua J Meeks3. 1. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: Richard.Matulewicz@nyulangone.org. 2. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 3. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
INTRODUCTION: The vast majority of patients who undergo a diagnostic evaluation for microscopic hematuria (MH) do not have occult bladder cancer. Identifying patients with MH at high risk of harboring bladder cancer can allow for a risk adjusted approach to diagnostic interventions with the goal of safely reducing unnecessary evaluations. METHODS: Patients with a new diagnosis of microhematuria during an 8.5 year period were retrospectively identified. All patients who had a complete MH evaluation were randomized to a training or a validation cohort. Logistic regression analysis was performed in the training cohort to identify factors related to a bladder cancer diagnosis and to develop our model. Receiver operating curves to identify bladder cancer were constructed for the training and validation cohort and tested for their ability to discriminate true cases. A nomogram to predict a bladder cancer diagnosis was created. RESULTS: In 4,178 patients split into training and validation cohorts, those diagnosed with bladder cancer were shown to be older, have a greater degree of MH (more RBC/hpf), and were former or current smokers. A nomogram created using this model was able to predict risk of a bladder cancer diagnosis with good discrimination (areas under the curve 0.79, 95% CI 0.75-0.83). A cutoff of 0.01 probability demonstrated a sensitivity of 99.1% and a negative predictive value of 99.7%. CONCLUSION: A nomogram can accurately predict the risk of bladder cancer diagnosed during the evaluation of MH and can potentially be used avoid a significant number of work ups in those at the lowest risk.
INTRODUCTION: The vast majority of patients who undergo a diagnostic evaluation for microscopic hematuria (MH) do not have occult bladder cancer. Identifying patients with MH at high risk of harboring bladder cancer can allow for a risk adjusted approach to diagnostic interventions with the goal of safely reducing unnecessary evaluations. METHODS:Patients with a new diagnosis of microhematuria during an 8.5 year period were retrospectively identified. All patients who had a complete MH evaluation were randomized to a training or a validation cohort. Logistic regression analysis was performed in the training cohort to identify factors related to a bladder cancer diagnosis and to develop our model. Receiver operating curves to identify bladder cancer were constructed for the training and validation cohort and tested for their ability to discriminate true cases. A nomogram to predict a bladder cancer diagnosis was created. RESULTS: In 4,178 patients split into training and validation cohorts, those diagnosed with bladder cancer were shown to be older, have a greater degree of MH (more RBC/hpf), and were former or current smokers. A nomogram created using this model was able to predict risk of a bladder cancer diagnosis with good discrimination (areas under the curve 0.79, 95% CI 0.75-0.83). A cutoff of 0.01 probability demonstrated a sensitivity of 99.1% and a negative predictive value of 99.7%. CONCLUSION: A nomogram can accurately predict the risk of bladder cancer diagnosed during the evaluation of MH and can potentially be used avoid a significant number of work ups in those at the lowest risk.
Authors: M Rodgers; J Nixon; S Hempel; T Aho; J Kelly; D Neal; S Duffy; G Ritchie; J Kleijnen; M Westwood Journal: Health Technol Assess Date: 2006-06 Impact factor: 4.014
Authors: Daniel Ramirez; Amit Gupta; Daniel Canter; Brian Harrow; Ryan W Dobbs; Victor Kucherov; Edward Mueller; Necole Streeper; Matthew A Uhlman; Robert S Svatek; Edward M Messing; Yair Lotan Journal: BJU Int Date: 2015-10-29 Impact factor: 5.588
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Rodney Davis; J Stephen Jones; Daniel A Barocas; Erik P Castle; Erich K Lang; Raymond J Leveillee; Edward M Messing; Scott D Miller; Andrew C Peterson; Thomas M T Turk; William Weitzel Journal: J Urol Date: 2012-10-24 Impact factor: 7.450
Authors: Ronald K Loo; Stephen F Lieberman; Jeff M Slezak; Howard M Landa; Albert J Mariani; Gary Nicolaisen; Ann M Aspera; Steven J Jacobsen Journal: Mayo Clin Proc Date: 2013-01-09 Impact factor: 7.616
Authors: Alan M Nieder; Yair Lotan; Geoffrey R Nuss; Joshua P Langston; Sachin Vyas; Murugesan Manoharan; Mark S Soloway Journal: Urol Oncol Date: 2008-12-20 Impact factor: 3.498
Authors: Christian Daniel Fankhauser; Sharon Waisbrod; Cindy Fierz; Anton S Becker; Benedikt Kranzbühler; Daniel Eberli; Tullio Sulser; Hugh Mostafid; Thomas Hermanns Journal: World J Urol Date: 2020-04-02 Impact factor: 4.226
Authors: Hannah Harrison; Juliet A Usher-Smith; Lanxin Li; Lydia Roberts; Zhiyuan Lin; Rachel E Thompson; Sabrina H Rossi; Grant D Stewart; Fiona M Walter; Simon Griffin; Yin Zhou Journal: Br J Gen Pract Date: 2021-12-31 Impact factor: 5.386